Fed Sparks Profit T...
Health Care: Drugs
Dynavax Technologies Corporation (DVAX: NASDAQ)
$2.54 0.01 | 0.40%
05/24/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 2.54 |
| 52 Week High | 5.10 |
| 52 Week Low | 1.74 |
| Avg. Daily Vol. (Mil) | 2.50 |
| Beta (3 year) | 2.58 |
| Share Related Items | |
| Mkt Cap (Mil) | 464.54 |
| Shares Out (Mil) | 182.89 |
| Float (Mil) | 121.57 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 6.30 |
| Current Ratio | 6.30 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 49.16 |
| Price/Book | 4.74 |
| Price/Cash Flow | -5.20 |
| Per Share Data | |
| Earnings | -0.41 |
| Sales | 0.05 |
| Book Value | 0.54 |
| Cash Flow | -0.49 |
| Business Summary | |
|---|---|
| Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. | |
| General Information | |
| 2929 Seventh Street
Suite 100 Berkeley, CA 94710-2753 |
|
| www.dynavax.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 167 | |
| CEO: Eddie Gray | |
| Short Interest | |
| Current Month (Mil) | 22.15 |
| Previous Month (Mil) | 22.33 |
| Short Interest Ratio (Days) | 11.30 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -75.90 |
| Return on Investments | -92.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with DVAX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Usercdm1
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorDrugs Facing FDA Approval i...
- Contributor10 Stocks Boosting Little F...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Stocks of Top-Performing...
Latest DVAX Headlines from TheStreet
- 5 Stocks Under $5 to Watch 03.13.13 | 07:03 am
- Stocks Waver as Investors Eye Italian Election 02.25.13 | 02:02 pm
- Dynavax May Seek Quick Re-File of HepB Vax Following FDA Rejection 02.25.13 | 07:02 am
- Stock Futures Point to Higher Open 02.25.13 | 07:02 am
- Run-Up Trade Into Dynavax's FDA Approval Decision 02.13.13 | 07:02 am
- Dynavax Options Trade For Heplisav FDA Approval Decision 02.12.13 | 08:02 am
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- 5 Stocks Under $10 Ready to Soar Higher 02.07.13 | 01:02 pm
- 'Mad Money' Lightning Round: I'm Avoiding Controversial Coinstar 02.07.13 | 06:02 am
- Cramer's 'Mad Money' Recap: Pay Attention 02.06.13 | 07:02 pm
Press Releases for DVAX
Partner Headlines for DVAX
- Why Dynavax's HEPLISAV Is Likely To Be Approved: Impact On Future Vaccine Development - Seeking Alpha 11.21.12 | 09:11 am
- Mid-Day Markets Update: Markets Recover on Fiscal Cliff Meeting; Casino Stocks Continue to Ramp - Benzinga 11.16.12 | 01:11 pm
- Dynavax Gets Crushed After Advisory Committee Vote - Seeking Alpha 11.16.12 | 09:11 am
- Cramer's Mad Money - 10 Things To Watch In The Week Ahead (9/14/12) - Seeking Alpha 09.16.12 | 06:09 am
- 3 Vaccine Companies With Upcoming Catalysts - Seeking Alpha 09.09.12 | 08:09 am
- Company News for May 10, 2012 - Corporate Summary - Zacks 05.10.12 | 10:05 am
- Buy And Sell Ideas Based On Monday's Big Biotech News Movers - Seeking Alpha 10.11.11 | 08:10 am
- Dynavax Reports Diabetic Subset Data From Modified Intent to Treat Analysis of the HEPLISAV Phase 3 Trial - Benzinga 10.06.11 | 04:10 pm
- 7 Breakout Stocks With Sufficient Cash to Cover Operating Expenses - Seeking Alpha 03.29.11 | 08:03 am
- Data from Dynavax for HBV Candidate - Analyst Blog - Zacks 12.27.10 | 01:12 pm
